Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
28.51
-0.92 (-3.13%)
At close: Sep 28, 2026, 4:00 PM EDT
29.14
+0.63 (2.21%)
Pre-market: Sep 29, 2026, 8:46 AM EDT
Adaptive Biotechnologies Revenue
Adaptive Biotechnologies had revenue of $71.55M in the quarter ending June 30, 2026, with 21.53% growth. This brings the company's revenue in the last twelve months to $308.08M, up 50.13% year-over-year. In the year 2025, Adaptive Biotechnologies had annual revenue of $276.98M with 54.77% growth.
Revenue (ttm)
$308.08M
Revenue Growth
+50.13%
P/S Ratio
14.77
Revenue / Employee
$493,720
Employees
624
Market Cap
4.55B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 276.98M | 98.02M | 54.77% |
| Dec 31, 2024 | 178.96M | 8.68M | 5.10% |
| Dec 31, 2023 | 170.28M | -15.03M | -8.11% |
| Dec 31, 2022 | 185.31M | 30.96M | 20.06% |
| Dec 31, 2021 | 154.34M | 55.96M | 56.88% |
| Dec 31, 2020 | 98.38M | 13.31M | 15.65% |
| Dec 31, 2019 | 85.07M | 29.41M | 52.83% |
| Dec 31, 2018 | 55.66M | 17.22M | 44.77% |
| Dec 31, 2017 | 38.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.27B |
| Qiagen | 2.10B |
| Sotera Health Company | 1.22B |
| NeoGenomics | 766.30M |
| Veracyte | 561.90M |
| CareDx | 458.09M |
| GeneDx Holdings | 454.43M |
| BillionToOne | 397.41M |
ADPT News
- 2 hours ago - Adaptive Biotechnologies initiated with a Buy at Goldman Sachs - TheFly
- 4 days ago - Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure - GlobeNewsWire
- 7 days ago - Adaptive Biotechnologies price target raised to $34 from $25 at BTIG - TheFly
- 12 days ago - Adaptive Biotechnologies reports update to NCCN guidelines for Multiple Myeloma - TheFly
- 12 days ago - Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ® - GlobeNewsWire
- 13 days ago - Adaptive Biotechnologies Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 27 days ago - Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science - GeekWire